The clinical trial is looking for contributions for this process. It is being called a “potential cure” but the results of the trial will further define that. 
This process involves boosting the immune system, and there are several biotech drugs in development that work the same process. The trial is based on a study done at Wake Forest and we all know what they also do there, they grow human organs and several folks are walking around with bladders grown in petri dishes.
Scientists At Wake Forest Grow a Mini Liver From Human Cells–Regenerative Medicine
Urethras Grown at Wake Forest–6 Years Later Five Young Men Are Doing Fine
The institute has requested funds and grants from the NIH and they are also looking for private contributions to get the trial moving. By boosting the white cell immune system they were able to “cure” mice who had cancer. The FDA approved this process for human trials. Based upon seeing mice cured, this looks to be very promising. They are looking for donors as well and have not had a problem finding healthy people who can give blood.
The home page for the clinical trials can be found here. When a qualified patient is identified, granulocytes are collected from 
“matched donors”. The institute also offers other cancer treatments to include leukemia, multiple myeloma and more. The patients participating in the trial will be those who have already tried conventional therapies and have not had a response. The trial page goes into detail as well about being a donor, the procedure and the two drugs administered during the process.
This is the first ever approved trial using this study protocol to sold tumor cancers. The video below is very good on explaining how cancer comes back and the ultimate goal here is to stop the process by giving the body enough power in their own system to fight back. The process sounds like it would make sense and if it works, well this could be a cure. BD
From the website:
“Our clinical protocol is based on a 1999 study conducted at Wake Forest University by Dr. Zheng Cui. Dr. Cui discovered a cancer resistant mouse. No matter how Dr. Cui attempted to infect this mouse with cancer, he couldn’t do it, the mouse’s immune system was just too strong. Forty percent of this mouse’s descendants
inherited the same significant cancer resistance. The white blood cells of these mice were able to seek out and destroy cancer cells not only in cell cultures, but also in living mice. Dr. Cui designed a test to measure this Cancer-Killing Activity, called CKA, and used those cells from cancer resistant mice to cure other mice with cancer. Further investigation showed that high levels of CKA granulocytes were also found in the white blood cells of some healthy people, specifically in the immune systems of young healthy humans around the age of eighteen to twenty-five.
White cell infusion therapy essentially translates the basis of Dr. Cui’s discovery into humans.
Instead of using white cells from mice whose immune system prevented them from developing cancer, we’re using the white cells taken from the immune systems of twenty year olds. If you take a twenty year old and you look at the incidence of cancer versus a seventy year old, a seventy year old has a one-hundred times greater risk of cancer. That’s because the immune system of young healthy donors are so much stronger. In theory, this study treatment may have the ability to supercharge the immune system using carefully cross-matched cancer-killing granulocytes donated by healthy young donors.”
Press Release:
Boynton Beach, FL, June 8, 2012 - Chances are, you know someone who has been diagnosed with cancer. One out of every three women will contract the disease in their lifetime; for men the odds are even greater. Now, an exciting new protocol has received approval from the FDA and WIRB (Western Institutional Review Board) to conduct a Phase I/II clinical trial on humans for treatment of solid tumor (metastic) cancers using a treatment designed to “supercharge the patient’s immune system and “zap” the cancer cells, destroying them.”
Leading the investigation is Dr. Dipnarine Maharaj, Director of the South Florida Bone Marrow and Stem Cell Transplant Institute in Boynton Beach, Florida. A hematologist and oncologist, Dr. Maharaj has been successfully treating patients with blood cancers for years using stem cell treatments. The clinical trials now underway target solid tumor cancers such as breast, cervical, stomach, pancreatic, lung, and melanoma.
As Dr. Maharaj explains, “A characteristic of a metastic cancer cell is the way it divides into twins. One of the twins will actually begin to form 
tissues while the other twin lies dormant. The standard therapy for treating metastatic tumors is chemotherapy. Chemotherapy will kill a certain number of tumor cells and those cells may shrink, so it will look as though you’re making progress, but with the immune system weak, the dormant twin can begin to form new tumors, which is why these cancers often return.
“Our protocol is based on a 1999 study conducted at Wake Forest University by my colleague, Dr. Zheng Cui. Dr. Cui discovered a cancer resistant mouse. No matter how many times Dr. Cui attempted to infect this mouse with cancer, he couldn’t do it; the mouse’s immune system was simply too strong. Further investigation showed that the mouse’s white cells possessed granulocytes – specialty cells that sought out cancer cells and eradicated them. These same granulocytes were also found in the white blood cells of humans, specifically in the immune systems of young, healthy people around the ages of nineteen through twenty-five. Our protocol is to treat metastic cancer patients with cancer killing granulocytes donated by young healthy cross-matched donors in order to repair or supercharge the patient’s immune system."
As promising as the new protocol sounds, there remains a funding hurdle to overcome. In recent years grant money from the National Institute of Health has been more difficult to obtain, and insurance companies do not pay for treatments during clinical trials.
To meet the financial challenge, the Institute has just launched a new website: www.ZapCancer.org which explains the protocol, provides vital answers for cancer patients, collects tax-deductible donations to fund the clinical trial, and contains a video presentation produced by N.Y. Times best-selling author, Steve Alten, whose father died from melanoma two weeks before he was to receive the protocol. Says Alten, “Cancer is a horrible disease that affects all of us. And yet, if a million people simply donated $10, the Institute could complete the first phases of this vitally important investigation, a necessary step to one day treating patients worldwide. For the simple cost of a movie ticket or paperback book, we could help fund a potential cure for solid tumor cancers. I pray that everyone will take a look at the ZapCancer.org website, make a small donation, and spread the link around.”
The bad news here though is there may not be enough to go around for a while as there has been issues with production so it’s approved and hopefully this will be remedied shortly. Usually it’s been the generic cancer drugs that have been short for patients and not an expensive name brand. The FDA is also requesting that future lots also be approved as some of the cells used to produce the drug were growing too slow. Genentech is also working on a 3rd drug for HER2 breast cancer and recently reported some positive clinical trial results. BD 
with standard glucose readings and test results. It appears to be a pretty good cross section of patients who met the criteria and it is part of a larger data sharing project called the Virtual Data Warehouse. The HMO Research Network is a group of 19 healthcare organizations who agree to standardize data sets from EHRs to collaborate and who is behind the Data Warehouse. BD 
week and had a great conversation with the folks from Objet. Both companies have no debt. I like the ability of 3D printers to make teeth myself having been one of those unlucky folks in life who has had to invest a lot of money in teeth. Objet already does digital dentistry with implants. 
person I don’t know that would certainly beat this as I really don’t think robots are a replacement at this place in time. It’s very creepy to watch the robotic arm move around to comfort the patient. The video shows the patient laying on a mattress on the floor of all things. You can read the entire story on this at the link but once the doctor leaves the room, the robot takes over. 
doctors and hospitals who have invested in electronic medical records, which is a very good thing; however when I see articles as such that tend to “hang” on technology for more immediate gratification than they can give at one time, I still question the mind set of some of our leaders and what their expectations are and if they are all attainable. I still keep looking around the web and can’t find a picture with a search that so much shows the secretary with so much as a cell phone in hand or her using some form of technology, why is this I ask? 
Last year I wrote about this same topic and now there’s a huge interest with drawing patients into the scenario and we still “got no role models” at the top and it’s still kind of carrying the tone of “its for those guys over there”. 
but there needs to be a little more data on side effects the article states. Sugar is sent from the body through urination which doesn’t’ normally happen until high glucose levels are reached. J and J has filed for regulatory clearance to sell the drug in the US. 
obesity rates push the condition to epidemic levels, affecting nearly 347 million people worldwide. While 10 different types of drugs are sold to treat diabetes, physicians still struggle to control their patients’ blood-sugar levels. 
network of community hospitals into the group. Both boards of each side still need to approve and it would also need regulatory approval as well. The downside of this is potential higher prices for consumers and limited options with contract negotiations. Reduced reimbursements and staying in business of course is what is behind such discussions and if such a merger were to take place, then comes buying up MD practices in the immediate area to again get a higher reimbursement fee with services provided at Medical System owned facilities. BD 
Medical Center, a highly specialized academic medical center, and Continuum Health Partners, a network of several community-oriented hospitals, including Beth Israel and the two St. Luke’s-Roosevelt campuses. 
compliant and allows for private conversations between patients and doctors. So many physicians already are set up via their EHR and just web services that already provide this so is there a market for this on a Facebook portal? 
many sources and includes a large number of journals. The video below tells more about how it works and it appears that it can definitely save some “search” time for doctors and it’s reliable information. 
a bunch of investors sinking money into “algorithms” and a case of “algorithms” that had issues and didn’t perform as they were supposed to. I don’t know how much longer it will take until someone wakes up to see that we can’t base an entire economy on “algorithms” which is seems is the forefront of what we have going on today. Sure algorithms have value but we seem to be thinking there’s some “magic carpet ride” here with making money. The carpet will ride for a while but it will need to come in for a landing here and there. 
coin, you have some very savvy folks at Facebook and I can’t help but wonder what they think as they write the stuff day in and day out too. Facebook has had their issues with privacy and applications and maybe their engineers should have a sit down with the engineers at NASDAQ. Here’s a bunch of links that describe how “algorithms” that you can’t see, touch, feel etc. affect consumers every day. When they are flawed, consumers become “data chasers” to go and fix whatever became flawed with information that most of the time they had nothing to do with the creation and much of it contains a “risk” factor of some sort built in that denies or creates some kind of access. 
who if you watch the video above are mentioned as the ones who dig in and get the bottom of this “mysterious” algorithm question all the time, and yet they don’t get enough recognition for all their “honest” analytic work that would help folks out in the long run. If you would like to see some of what they had to say, 
I made an “opinion” post asking if “we need a Department of Algorithms”…maybe we are there as there are those algos created for “desired” results and those that generate “accurate” results and the two should be the same, but they are not always. Read this book on how some of this works from Twitter bud Professor Siefe at NYU, as he nails it pretty well. 
fix is only partial and folks at NASDAQ may seem to forget how integrated we are today and the impact the failure had on other transactions. Why in the world can we not have heavily accredited IT and computer code folks running the show instead of CEO figureheads that have never written a stick of code? Even the Madoff IT folks had it dialed in with computer coding, they said so too and were paid well for “flawed code” that hid certain items and kept the false store front going. 
May of 2010 that they were going to hand out dividends on a more frequent basis, and as you can see from the headline, no caps on executive earnings. So it appears the shareholder dividend is again about ready to grow. With all the “owned” subsidiaries the company owns today, there’s almost not a portion of healthcare they don’t touch in some way to include owning physicians groups, owning a company in China to promote Chinese drugs and devices in the US and worldwide to recently setting up another subsidiary to distribute “cheap” hearing aids. You can see some of that action with a no cost hearing aid for seniors in some areas who sign up for some of their Medicare Part D plans. Last but not least we can’t forget their extensive analytics and code folks who have been at this for years with Optum, formerly known as Ingenix who make a lot of money with software and selling data. BD 
explained what this test is. You may have cancer in your lung for example, but it may not have originated there and this test will be able to identify if it by chance came from somewhere else in your body, which makes a huge difference with treatments as one medication that treats lung cancer may be quite different from one that treats let’s say kidney cancer for an example. Lab results can be done in 10 days or less. You can read my original interview below for more information. 
to help it explore "strategic options," including a possible sale of the company. 
but his creation of synthetic cells is all over the news from time to time. Juan states and emphasizes how “fast” this is all moving and it really is. Actually back in December of 2010, this was the big announcement made by Venter and he too is a guest on several of the TED conventions. The group also includes current NIH Director, Francis Collins when it comes to “cracking the code”. 
I had not heard of this site and anyone can join so I did and those who are not physicians are able to read most of the content on the site for information and incentives areas for CMS of course are limited to the physicians. Again being the first time I have seen the site it looks to have “credible” information and there’s already a good size membership online too. If you don’t know who Dr. Halamka is, here’s an interview from HealthSystemCIO in 2011 that will tell you more. BD 
conditions for moving back-end processes to a cloud-based solution. By fully leveraging Windows Azure, the National Kidney Registry is continuing its amazing work of helping to provide a long and normal life for the ultimate benefactors of this endeavor – those among us who need the help of the community to overcome end-stage renal disease”. 
Research Director for National Kidney Registry said, “More and more transplant centers are using kidney paired exchange transplantation to help their patients in kidney failure, and the computational power required to support the sophisticated matching algorithms that sift through and evaluate all the potential matches has been growing exponentially”.
![EZClaim[4]](http://lh4.ggpht.com/_v3zjJigoAPE/TG1-9etl5ZI/AAAAAAAAgqg/CRMlet5Pi5k/EZClaim44.png?imgmax=800 "EZClaim[4]")
Math–This Could be a Subject for Michael Moore to Explore and Document In a Movie
Screenings Too–Killer Algorithms Part 12–Medical Billing Codes Style
Assessing Consumer Credit Scores–Attack of the Killer Algorithms Chapter 21 With Flawed Data
Duping” Society Combined With A World of Rogue Algorithms & Flawed Data Continues In Markets As Seen With Knight Capital This Week-Attack of the Killer Algorithms Chapter 36
Study Fraud With EHR Technologies, Namely Medical Records/Billing Software Used by Hospitals– HHS And SEC Continue Getting Their Non-Algorithmic Fannies Kicked–Attack of the Killer Algorithms Chapter 46
SilverScript Senior Drug Program Sanctioned by Medicare Until the Payment And Billing Algorithms are Cleaned Up-Killer Algorithms Chapter 53
